TY - JOUR
T1 - Robustness Analysis for External Beam Radiation Therapy Treatment Plans
T2 - Describing Uncertainty Scenarios and Reporting Their Dosimetric Consequences
AU - Yock, Adam D.
AU - Mohan, Radhe
AU - Flampouri, Stella
AU - Bosch, Walter
AU - Taylor, Paige A.
AU - Gladstone, David
AU - Kim, Siyong
AU - Sohn, Jason
AU - Wallace, Robert
AU - Xiao, Ying
AU - Buchsbaum, Jeff
N1 - Funding Information:
Sources of support: This project was supported by grants NRG Operations (U10CA180868) and IROC (U24CA180803) from the National Cancer Institute.Conflicts of interest: Drs Yock, Mohan, Flampouri, Gladstone, Wallace, Xiao, and Buchsbaum have no conflicts of interest to disclose. Dr Bosch reports grants from the National Cancer Institute during the conduct of the study. Dr Sohn reports a National Institutes of Health/National Cancer Institute R01 Grant (CA187053-01A1). Dr Kim reports other from Medical Tool and Technology, LLC, outside of the submitted work. Mrs. Taylor reports grant support from the federal share of income earned by the Massachusetts General Hospital Proton Therapy Research and Treatment Center (contract C06 CA059267) and Public Health Service (grant CA180803), awarded by the U.S. Department of Health and Human Services, National Cancer Institute. Sources of support: This project was supported by grants NRG Operations (U10CA180868) and IROC (U24CA180803) from the National Cancer Institute. Conflicts of interest: Drs Yock, Mohan, Flampouri, Gladstone, Wallace, Xiao, and Buchsbaum have no conflicts of interest to disclose. Dr Bosch reports grants from the National Cancer Institute during the conduct of the study. Dr Sohn reports a National Institutes of Health/ National Cancer Institute R01 Grant ( CA187053-01A1). Dr Kim reports other from Medical Tool and Technology, LLC, outside of the submitted work. Mrs. Taylor reports grant support from the federal share of income earned by the Massachusetts General Hospital Proton Therapy Research and Treatment Center (contract C06 CA059267) and Public Health Service (grant CA180803), awarded by the U.S. Department of Health and Human Services, National Cancer Institute.
Funding Information:
Sources of support: This project was supported by grants NRG Operations (U10CA180868) and IROC (U24CA180803) from the National Cancer Institute.Conflicts of interest: Drs Yock, Mohan, Flampouri, Gladstone, Wallace, Xiao, and Buchsbaum have no conflicts of interest to disclose. Dr Bosch reports grants from the National Cancer Institute during the conduct of the study. Dr Sohn reports a National Institutes of Health/National Cancer Institute R01 Grant (CA187053-01A1). Dr Kim reports other from Medical Tool and Technology, LLC, outside of the submitted work. Mrs. Taylor reports grant support from the federal share of income earned by the Massachusetts General Hospital Proton Therapy Research and Treatment Center (contract C06 CA059267) and Public Health Service (grant CA180803), awarded by the U.S. Department of Health and Human Services, National Cancer Institute.
Funding Information:
Sources of support: This project was supported by grants NRG Operations (U10CA180868) and IROC (U24CA180803) from the National Cancer Institute .
Funding Information:
Conflicts of interest: Drs Yock, Mohan, Flampouri, Gladstone, Wallace, Xiao, and Buchsbaum have no conflicts of interest to disclose. Dr Bosch reports grants from the National Cancer Institute during the conduct of the study. Dr Sohn reports a National Institutes of Health / National Cancer Institute R01 Grant ( CA187053-01A1 ). Dr Kim reports other from Medical Tool and Technology, LLC, outside of the submitted work. Mrs. Taylor reports grant support from the federal share of income earned by the Massachusetts General Hospital Proton Therapy Research and Treatment Center (contract C06 CA059267) and Public Health Service (grant CA180803 ), awarded by the U.S. Department of Health and Human Services, National Cancer Institute.
Publisher Copyright:
© 2018
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Purpose: With external beam radiation therapy, uncertainties in treatment planning and delivery can result in an undesirable dose distribution delivered to the patient that can compromise the benefit of treatment. Techniques including geometric margins and probabilistic optimization have been used effectively to mitigate the effects of uncertainties. However, their broad application is inconsistent and can compromise the conclusions derived from cross-technique and cross-modality comparisons. Methods and Materials: Conventional methods to deal with treatment planning and delivery uncertainties are described, and robustness analysis is presented as a framework that is applicable across treatment techniques and modalities. Results: This report identifies elements that are imperative to include when conducting a robustness analysis and describing uncertainties and their dosimetric effects. Conclusion: The robustness analysis approach described here is presented to promote reliable plan evaluation and dose reporting, particularly during clinical trials conducted across institutions and treatment modalities.
AB - Purpose: With external beam radiation therapy, uncertainties in treatment planning and delivery can result in an undesirable dose distribution delivered to the patient that can compromise the benefit of treatment. Techniques including geometric margins and probabilistic optimization have been used effectively to mitigate the effects of uncertainties. However, their broad application is inconsistent and can compromise the conclusions derived from cross-technique and cross-modality comparisons. Methods and Materials: Conventional methods to deal with treatment planning and delivery uncertainties are described, and robustness analysis is presented as a framework that is applicable across treatment techniques and modalities. Results: This report identifies elements that are imperative to include when conducting a robustness analysis and describing uncertainties and their dosimetric effects. Conclusion: The robustness analysis approach described here is presented to promote reliable plan evaluation and dose reporting, particularly during clinical trials conducted across institutions and treatment modalities.
UR - http://www.scopus.com/inward/record.url?scp=85061035265&partnerID=8YFLogxK
U2 - 10.1016/j.prro.2018.12.002
DO - 10.1016/j.prro.2018.12.002
M3 - Review article
C2 - 30562614
AN - SCOPUS:85061035265
SN - 1879-8500
VL - 9
SP - 200
EP - 207
JO - Practical Radiation Oncology
JF - Practical Radiation Oncology
IS - 4
ER -